Processa Pharmaceuticals Inc (PCSA)

$3.51 +0.15 (4.46%)
Market Cap 7.61M
Revenue (ttm) 0.00
Net Income (ttm) -11.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 133,100
Avg Vol 1,003,855
Day's Range N/A - N/A
Shares Out 2.27M
Stochastic %K 13%
Beta 1.09
Analysts Sell
Price Target $25.00

Company Profile

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical t...

Industry: Biotechnology
Sector: Healthcare
Phone: 443 776 3133
Fax: 443 288 4420
Address:
7380 Coca Cola Drive, Suite 106, Hanover, United States
Tetoooo
Tetoooo Dec. 24 at 9:35 PM
$PCSA they ll run out of money in 6 months so they ll either push the price higher and dump or just dump to get more money. Their cash burning rate is high
1 · Reply
Tetoooo
Tetoooo Dec. 24 at 3:14 PM
$PCSA one mor pump before the dump!! Or partnership or buyout. Hmmm or just dump from here
1 · Reply
TheDrunkTrader69
TheDrunkTrader69 Dec. 24 at 1:51 PM
$PCSA do your own due diligence but when I said whales where gobbling shares i knew it would come out, there are now 23 with stonepine owning 45% waitng until the shorts have to cover when 1 small PR pops 25 to 30 inbound. https://www.nasdaq.com/articles/processa-pharmaceuticals-pcsa-price-target-increased-240000-2550
1 · Reply
DeviationDave
DeviationDave Dec. 24 at 12:25 PM
$PCSA Sentiment could pivot sharply depending on how progress validates the underlying thesis beyond narrative appeal. Long-term optimism depends on disciplined follow-through.
0 · Reply
Jjjjen
Jjjjen Dec. 24 at 12:13 PM
$PCSA i'm in at 5.1 ....should I average down or wait here
1 · Reply
smalltraderjoe
smalltraderjoe Dec. 24 at 12:14 AM
$PCSA Their Phase 2 data is really encouraging. I understand that they they have recently dine s r/s but why the atock price is slipping? Every dy it will be green in the beginning and then starts dropping like a rock . Almost No shortable shares available. There could be some reason why some big funds are shorting it do hard . Anyone cares to shed some light?
1 · Reply
CelticBeast
CelticBeast Dec. 23 at 10:53 PM
$PCSA anyone buying here😏
1 · Reply
FullPorrtDipz
FullPorrtDipz Dec. 23 at 6:04 PM
If you like getting in them before the massive moves.. Drop @MomentumZeus a FOLLOW below. He's been calling some insane runners lately.. 🚀 Bulls volume on $PCSA $MOVE.X $XTKG $NTLA
0 · Reply
Rampageusa
Rampageusa Dec. 23 at 5:30 PM
$PCSA, $PBM Consolidating, expect a boom soon in few days or today, same for $CETX… Is that P letter ralated stocks day today..?
0 · Reply
TheDrunkTrader69
TheDrunkTrader69 Dec. 23 at 3:45 PM
$PCSA hard to say when but 25.50 is target price, investors slowing gobbling up shares, good Pr will send it. When it goes its going hard.
2 · Reply
Latest News on PCSA
Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data?

Dec 17, 2025, 1:10 PM EST - 7 days ago

Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data?

Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer

Dec 17, 2025, 8:00 AM EST - 7 days ago

Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer

Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025

Nov 5, 2025, 9:15 AM EST - 7 weeks ago

Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025

Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies

Aug 7, 2025, 8:30 AM EDT - 4 months ago

Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies

Processa Pharmaceuticals Provides Portfolio and Business Update

Jul 1, 2025, 9:00 AM EDT - 6 months ago

Processa Pharmaceuticals Provides Portfolio and Business Update

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

Jun 17, 2025, 12:26 PM EDT - 6 months ago

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate

Jun 17, 2025, 9:00 AM EDT - 6 months ago

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate

Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

Jun 13, 2025, 8:00 AM EDT - 6 months ago

Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

May 30, 2025, 9:00 AM EDT - 7 months ago

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025

Apr 15, 2025, 8:00 AM EDT - 9 months ago

Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Mar 18, 2025, 8:30 AM EDT - 10 months ago

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

Feb 7, 2025, 8:00 AM EST - 11 months ago

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Jan 30, 2025, 5:17 PM EST - 11 months ago

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Jan 27, 2025, 8:30 PM EST - 11 months ago

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Oct 2, 2024, 4:05 PM EDT - 1 year ago

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

Jun 11, 2024, 8:20 AM EDT - 1 year ago

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

May 6, 2024, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting

Mar 25, 2024, 8:15 AM EDT - 1 year ago

Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Feb 21, 2024, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

Feb 14, 2024, 1:00 PM EST - 2 years ago

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 6, 2024, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

Feb 1, 2024, 4:22 PM EST - 2 years ago

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

Jan 26, 2024, 9:04 AM EST - 2 years ago

Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

What made Processa Pharmaceuticals stock nearly triple on Thursday?

Jan 25, 2024, 11:29 AM EST - 2 years ago

What made Processa Pharmaceuticals stock nearly triple on Thursday?

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

Jan 25, 2024, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

Jan 19, 2024, 7:45 AM EST - 2 years ago

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split

Jan 18, 2024, 7:45 AM EST - 2 years ago

Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split

Processa Pharmaceuticals to Present at the Biotech Showcase 2024

Jan 2, 2024, 5:06 PM EST - 2 years ago

Processa Pharmaceuticals to Present at the Biotech Showcase 2024

Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine

Dec 19, 2023, 9:00 AM EST - 2 years ago

Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine

Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine

Dec 13, 2023, 9:00 AM EST - 2 years ago

Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine

Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference

Nov 30, 2023, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference

Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook

Nov 29, 2023, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Nov 13, 2023, 1:40 PM EST - 2 years ago

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas

Nov 9, 2023, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas

Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders

Nov 1, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders

Processa Pharmaceuticals to Present at the ThinkEquity Conference

Oct 13, 2023, 1:08 PM EDT - 2 years ago

Processa Pharmaceuticals to Present at the ThinkEquity Conference

Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care

Aug 17, 2023, 8:05 AM EDT - 2 years ago

Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care

Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference

Aug 10, 2023, 4:15 PM EDT - 2 years ago

Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference

Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer

Aug 8, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer

Next Generation Chemotherapy: Improved Treatment for More Patients

Jun 14, 2023, 4:15 PM EDT - 2 years ago

Next Generation Chemotherapy: Improved Treatment for More Patients

Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress

May 22, 2023, 8:05 AM EDT - 2 years ago

Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress

Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative

May 18, 2023, 8:00 AM EDT - 2 years ago

Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative

Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting

Apr 28, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting

Processa Pharmaceuticals, Inc. (PCSA) Q4 2022 Earnings Call Transcript

Mar 31, 2023, 4:14 PM EDT - 2 years ago

Processa Pharmaceuticals, Inc. (PCSA) Q4 2022 Earnings Call Transcript

Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results

Mar 30, 2023, 4:01 PM EDT - 2 years ago

Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results

Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST

Mar 23, 2023, 8:30 AM EDT - 2 years ago

Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST

Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine

Mar 17, 2023, 8:30 AM EDT - 3 years ago

Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine

Tetoooo
Tetoooo Dec. 24 at 9:35 PM
$PCSA they ll run out of money in 6 months so they ll either push the price higher and dump or just dump to get more money. Their cash burning rate is high
1 · Reply
Tetoooo
Tetoooo Dec. 24 at 3:14 PM
$PCSA one mor pump before the dump!! Or partnership or buyout. Hmmm or just dump from here
1 · Reply
TheDrunkTrader69
TheDrunkTrader69 Dec. 24 at 1:51 PM
$PCSA do your own due diligence but when I said whales where gobbling shares i knew it would come out, there are now 23 with stonepine owning 45% waitng until the shorts have to cover when 1 small PR pops 25 to 30 inbound. https://www.nasdaq.com/articles/processa-pharmaceuticals-pcsa-price-target-increased-240000-2550
1 · Reply
DeviationDave
DeviationDave Dec. 24 at 12:25 PM
$PCSA Sentiment could pivot sharply depending on how progress validates the underlying thesis beyond narrative appeal. Long-term optimism depends on disciplined follow-through.
0 · Reply
Jjjjen
Jjjjen Dec. 24 at 12:13 PM
$PCSA i'm in at 5.1 ....should I average down or wait here
1 · Reply
smalltraderjoe
smalltraderjoe Dec. 24 at 12:14 AM
$PCSA Their Phase 2 data is really encouraging. I understand that they they have recently dine s r/s but why the atock price is slipping? Every dy it will be green in the beginning and then starts dropping like a rock . Almost No shortable shares available. There could be some reason why some big funds are shorting it do hard . Anyone cares to shed some light?
1 · Reply
CelticBeast
CelticBeast Dec. 23 at 10:53 PM
$PCSA anyone buying here😏
1 · Reply
FullPorrtDipz
FullPorrtDipz Dec. 23 at 6:04 PM
If you like getting in them before the massive moves.. Drop @MomentumZeus a FOLLOW below. He's been calling some insane runners lately.. 🚀 Bulls volume on $PCSA $MOVE.X $XTKG $NTLA
0 · Reply
Rampageusa
Rampageusa Dec. 23 at 5:30 PM
$PCSA, $PBM Consolidating, expect a boom soon in few days or today, same for $CETX… Is that P letter ralated stocks day today..?
0 · Reply
TheDrunkTrader69
TheDrunkTrader69 Dec. 23 at 3:45 PM
$PCSA hard to say when but 25.50 is target price, investors slowing gobbling up shares, good Pr will send it. When it goes its going hard.
2 · Reply
bobbydoles
bobbydoles Dec. 23 at 3:42 PM
$PCSA when pump to $20 $FJET $ASTI $SIDU wouldnt take much!
0 · Reply
merlin8121
merlin8121 Dec. 23 at 3:15 PM
$PCSA https://www.merlintrader.com/pcsa-processa/
0 · Reply
Rampageusa
Rampageusa Dec. 23 at 2:34 PM
$AFJK - 90+,$PCSA 7.5/9.5
1 · Reply
Juve82a
Juve82a Dec. 23 at 12:57 PM
$PCSA
0 · Reply
Takeiteasy30
Takeiteasy30 Dec. 23 at 12:38 PM
$TNMG News before unhalt from RS - perfect blend for pump.Float now 1.56 mln shares. They did the same with $PCSA last week - news right before unhalt from RS and pump in first minute candle like crazy. Lets see here - loaded yesterday lottery ticket finger crossed on that little gamble .
1 · Reply
Theyonly
Theyonly Dec. 23 at 6:23 AM
$PCSA I've been waiting for product or clinical updates on the website ever since I bought Pcsa earlier this year. I'm writing to hear your thoughts because it seems like something has been happening recently. Originally, the product pipeline on the Pcsa homepage had PCS499 and it's gone now. After the news about PCS499 came out on November 5th. What happened? Did the PCS499 technology sell or did it stop clinical trials? We'd like to hear your opinion.
1 · Reply
FullPorrtDipz
FullPorrtDipz Dec. 23 at 1:57 AM
If you like getting in them before the massive moves.. Drop @MomentumZeus a FOLLOW below. He's been calling some insane runners lately.. 🚀 Good squeezers: $PCSA $ABTC $AKAN $DRCT
0 · Reply
Jwa68
Jwa68 Dec. 22 at 9:12 PM
$PCSA Still expecting a possible very ugly financing soon. Also watch that lawsuit over their main drug 6422. Do your due diligence. The shares didnt go from about $200 plus to 15 cents split adjusted because management has a lived up to promises.
0 · Reply
ranthor
ranthor Dec. 22 at 5:31 PM
$PCSA hey imbecile…how’s the flight?
0 · Reply
topstockalerts
topstockalerts Dec. 22 at 5:29 PM
$PCSA small caps continue to run..
1 · Reply
satrasal
satrasal Dec. 22 at 4:37 PM
$PCSA H.C. Wainwright (Dec 21) reiterated a Buy with a split-adjusted $25.50 target. Selvaraju cites "de-risked" Phase 2 data showing NGC-Cap delivers superior cancer-killing exposure while reducing toxic FBAL catabolites by 10-fold. This uncouples efficacy from dose-limiting side effects, positioning $PCSA as a safer, higher-potency chemotherapy backbone for metastatic breast cancer.
0 · Reply
InsaneGainz
InsaneGainz Dec. 22 at 4:04 PM
$PCSA could get jumpy from here.
1 · Reply